New obesity drug from Lilly delivers major weight loss
An investigational obesity drug from Eli Lilly cleared important end points in a late-stage trial, the company said Thursday, by helping patients lose up to 30 percent of their body weight. Lilly said that a once-weekly injection of retatrutide met the primary endpoint in a Phase 3 clinical trial, as well as key secondary end points for obesity, delivering clinically meaningful weight loss. The highest dose of retatrutide helped patients…
An investigational obesity drug from Eli Lilly cleared important end points in a late-stage trial, the company said Thursday, by helping patients lose up to 30 percent of their body weight. Lilly said that a once-weekly injection of retatrutide met the primary endpoint in a Phase 3 clinical trial, as well as key secondary end points for obesity, delivering clinically meaningful weight loss. The highest dose of retatrutide helped patients…
An investigational obesity drug from Eli Lilly cleared important end points in a late-stage trial, the company said Thursday, by helping patients lose up to 30 percent of their body weight. Lilly said that a once-weekly injection of retatrutide met the primary endpoint in a Phase 3 clinical trial, as well as key secondary end points for obesity, delivering clinically meaningful weight loss. The highest dose of retatrutide helped patients…
The full story continues on The Hill.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.